Portfolio | Indago Research

18 years or older

Runny nose, cough, congestion, wheezing? Learn about a clinical trial for RSV

Worried about RSV?

Contact a clinical trial site and get tested today at no cost to see if you qualify for the study

Indago Research

786-772-0510

3700 W 12th ave, suite 300 Hialeah FL 33012

RSV can be a serious, life-threatening virus for high-risk adults who are 18 years or older and meet at least 1 of the following criteria:

Moderate or severe COPD
Asthma
Chronic lung disease
Chronic cardiovascular disease
≥60 years of age (vaccinated or nonvaccinated)

Why join an RSV clinical trial?

Access to an investigational oral medication for RSV

Limited treatment options for high-risk adults
No FDA-approved oral treatment available
Don’t have to discontinue current medications to participate

It’s important to get your RSV status confirmed quickly.

To be eligible for the study, you must be diagnosed with RSV and enrolled within 3 days of your symptoms starting.

18-55 years old BED

Do you have binge eating disorder?

This study is evaluating an oral investigational medication (solriamfetol) in adults with BED. Solriamfetol is approved by the FDA for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA), which are sleep-related disorders. Solriamfetol is an investigational treatment for BED, meaning it has not yet been approved by any health authority for the treatment of BED.

18 to 75 years old Overweight

Are you interested in participating in this clinical trial?

Controlled Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants with Obesity or Overweight

18 years or older CKD

Do you have chronic kidney disease (CKD) and are having trouble controlling your blood pressure?

We are looking for people who are affected by both hypertension and chronic kidney disease to participate in a research study to investigate a new experimental treatment. The research study is called EXPLORE-CKD

You may qualify if you:

Have been diagnosed with hypertension and chronic kidney disease
Are taking medication for hypertension
Have abnormal kidney tests showing too much albumin (a type of protein) in your urine

Consider participating in the EXPLORE-CKD research study for a chance to contribute to research that may lead to more effective treatment options for high blood pressure and chronic kidney disease.

Choosing to participate in a clinical research study is an important decision. The information obtained from the EXPLORE-CKD study may help advance the treatment of future patients with high blood pressure and chronic kidney disease; and will provide important information about how well people respond to the study drug being investigated.

All clinical research studies are highly regulated to try to protect your safety and human rights. The research team can help explain this to you in further detail so that you are fully informed about the study before you decide whether you would like to participate.

What do I do next?

The EXPLORE-CKD Clinical Study is currently looking for interested study participants.

FOR MORE INFORMATION

786-772-0510

50 to 80 years of age Dementia

Problems with memory could be early Alzheimer’s. The time to act is now.

Learn about the TargetTau-1 clinical study.

Are you or someone you know experiencing early symptoms of memory loss (mild cognitive impairment) or Alzheimer’s disease?

While there is no known cure for Alzheimer’s disease (AD), scientists have made huge progress in understanding AD and finding new routes for treatment, which can be achieved through clinical trials.

We are recruiting participants for the TargetTau-1 study. This clinical research study is testing a new, investigational medicine for mild cognitive impairment or mild early AD.

You may qualify for this study if you:

Are 50-80 years old
Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease, or have mild Alzheimer’s dementia
Have a study partner with whom you spend at least 8 hours per week (such as a spouse, friend, or an adult child) who can attend some study visits with you during the study and provide follow-up information.

The study doctor will also check other eligibility requirements.

Participation in the study lasts about 2 years and requires regular visits to the research clinic to receive study drug and monitor your health and AD status. If you decide to take part in the study, all study-related drugs and procedures will be provided to you at no cost. Participation is voluntary and you would be able to leave the study at any point. To learn more and see if you are eligible, please contact: 786-772-0510

To learn more about this Alzheimer’s disease clinical study, visit: bmsclinicaltrials.com/TargetTau1

18 to 75 years old Diabetes Obesity Overweight

A clinical research study for people with obesity or overweight and type 2 diabetes

LAA2 is a new clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) may help treat people with obesity or overweight and type 2 diabetes.

50-64 years of age

Potentially Help Prevent Seasonal Flu and COVID-19 With a Single Injection

The Duo P201 Trial will evaluate the safety and immune response of 4 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.

50-64 years of age 65+ years

Streptococcus Pneumoniae Vaccine

Streptococcus pneumoniae is a common type of bacteria (germ) that can cause a wide variety of diseases, ranging from mild sinus and ear infections to more serious infections of the lungs, lining of the brain, or blood that require hospitalization and can be life-threatening. While anyone can get pneumococcal disease, adults over 50 have a higher risk of experiencing severe illness and are 8 times more likely to be hospitalized with pneumococcal pneumonia than younger adults.

According to the Centers for Disease Control and Prevention (CDC), getting vaccinated is the best way to help protect against pneumococcal disease. The CDC recommends that adults 65 years of age and older receive a pneumococcal vaccine as part of their routine vaccinations.

The vaccines available today protect against many strains of pneumococcal bacteria, but not all of them. That’s why we thought you may be interested in learning about Pfizer’s pneumococcal vaccine clinical trial designed to broaden protection against more bacterial strains.

We’re currently enrolling people who are:

50 to 64 years of age and have not previously received a pneumococcal vaccine.
65 years of age or older and have either not received a pneumococcal vaccine or have received the PNEUMOVAX® 23 vaccine more than 5 years ago.

Taking part in this clinical trial could potentially improve vaccine protection not only for you, but also others in the future.

Interested in joining this study? Here’s what you can expect if you take part:

The study will last about one year, and you will attend at least 4 study visits.
You will be randomly assigned to receive one dose of either the study vaccine or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®). You have an equal chance of being assigned to either vaccine group. There is no placebo (a shot with no active ingredient) in this study.
Your safety is always our top priority. Our medical team will closely monitor your health while you are in the study. You can also leave this clinical trial at any time and for any reason.
There is no cost to participate, and health insurance is not required. You will also be paid for completing study-related activities.

Please contact our team for more information. We’ll review the study’s requirements with you to help you decide if this clinical trial is a good fit for you.

786-772-0510

18 - 49 years old 60 years of age or older

Did you know that flu viruses change every year?

Did you know that flu viruses change every year? That’s why yearly vaccination is the most effective way to help prevent flu and its complications.

18- 65 years old Depressed

Recruiting Participants for the PARADIGM Depression Research Study

Are you living with major depressive disorder (MDD)? Are you experiencing persistent sadness, hopelessness, irritability, restlessness, guilt or worthlessness? Indago is collaborating with Axsome Therapeutics on a research study to assess the safety of solriamfetol in adults with depression (SOL-MDD-301 or PARADIGM).

Older Posts